Cerus Corporation reported total revenue of $60.2 million for the third quarter of 2025, a 19% increase compared to $50.7 million in the same period of 2024. Product revenue rose 15% year-over-year to $52.7 million, driven by growth in IFC and global platelet sales. Government contract revenue reached $7.5 million, up 63% from the prior year, primarily due to funding for research and development activities related to the INTERCEPT RBC program and next-generation pathogen reduction technology. The company's GAAP net loss narrowed to $0.02 million for the third quarter, compared to a net loss of $2.9 million in the same period last year. Non-GAAP adjusted EBITDA was positive at $5.0 million, up from $4.4 million a year ago. As of September 30, 2025, cash, cash equivalents, and short-term investments totaled $78.5 million.